Law firms Skadden, Freshfields and Davis Polk take the lead as blockbuster Pfizer/AstraZeneca deal gears up again Jaishree Kalia · 28 April 2014 · 2 min read Corporate and M&A Davis Polk Freshfields Skadden, Arps, Slate, Meagher & Flom Skadden, Arps, Slate, Meagher & Flom, Freshfields Bruckhaus Deringer and Davis Polk & Wardwell have all landed lead roles advising Pfizer and AstraZeneca as talks over a potential $100bn merger resurface.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryHSF Kramer, Addleshaws and Quinn chief take top prizes at Legal Business AwardsLaw firmsNews Editor30 Sep 2026Weil recruits Frankfurt corporate partner in latest European exit for FreshfieldsLaw firmsEliza Winter21 Sep 2026Senior CEE partner leaves Freshfields for White & CaseLaw firmsEliza Winter18 Sep 2026‘People need to feel it’ – Reed Smith chiefs on upping the firm’s ambitionLaw firmsTom Cox29 Sep 2026Trading Places: Gibson Dunn picks up Paul Weiss disputes trio as Latham finance pair move to V&ELaw firmsWill Lewallen25 Sep 2026A&O Shearman and HSFK lead as Airtel plans landmark London IPOLaw firmsWill Lewallen24 Sep 2026Revolving doors: Simpson Thacher, Latham, Sidley lead New Year London movesLaw firmsAnna Huntley9 Jan 2025Five partners vie to succeed Hoyland as Simmons managing partnerLaw firmsTom Cox7 Jan 2025‘Seize every opportunity’ – Paul Hastings partner Reena Gogna on City law, Suits and poetryLaw firmsAnna Huntley7 Jan 2025